MedTrace Logo

A Study of NX-1607 in Adults With Advanced Malignancies

NCT05107674 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2025-09-09

No results posted yet for this study

Summary

This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.

Conditions

  • Ovarian Cancer, Epithelial
  • Gastric Cancer
  • GastroEsophageal Junction (GEJ) Cancer
  • Head and Neck Squamous Cell Carcinoma
  • Metastatic or Unresectable Melanoma
  • Non-small Cell Lung Cancer (NSCLC)
  • Metastatic Castration-resistant Prostate Cancer (mCRPC)
  • Malignant Pleural Mesothelioma (MPM)
  • Triple Negative Breast Cancer (TNBC)
  • Metastatic Urothelial Carcinoma
  • Cervical Cancer
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Richter Transformation
  • Microsatellite Stable Colorectal Carcinoma

Interventions

DRUG

NX-1607

Oral NX-1607

DRUG

Paclitaxel

Paclitaxel IV

Sponsors & Collaborators

  • Nurix Therapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Linda Neuman, MD · Nurix Therapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-29
Primary Completion
2026-08-31
Completion
2028-02-28
FDA Drug
Yes

Countries

  • United States
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05107674 on ClinicalTrials.gov